The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Fracture risk in older DLBCL patients after R-CHOP
Diffuse large B-cell lymphoma (DLBCL) and osteoporotic fracture occur more frequently in older patients. Steroids and chemotherapy are recognized as a risk factor for fragility-related fractures. Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses a study designed to better define the risk of fracture following front line R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) immunochemotherapy in older patients with DLBCL. Data shows there is a clinically relevant fracture risk in older DLBCL patients specifically receiving R-CHOP in early follow-up. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
